Formation of plaques in artery walls, or atherogenesis, is known to lead to cardiovascular disease risk and heart disease. Low-density lipoproteins (LDLs), which deliver cholesterol to inflammatory cells in blood vessels, are linked to disease, which is commonly managed using cholesterol-lowering therapies. Whether increasing levels of high-density lipoproteins (HDLs), which remove cholesterol from the circulation, can be cardioprotective has not been clear, despite early clinical studies showing evidence for a positive effect in cardiovascular disease. In 'Bench to Bedside', Daniel J. Rader and Alan R. Tall discuss how the field should focus on promoting reverse cholesterol transport that would result in cholesterol efflux from macrophages to biliary excretion rather than simply trying to increase HDL cholesterol levels. Understanding how different molecular mechanisms operate in this 'HDL flux hypothesis' will uncover ways to develop HDL-targeted therapeutics that will protect from cardiovascular and heart disease. In 'Bedside to Bench', Jay W. Heinecke peruses clinical studies to propose better and simpler ways to measure reverse cholesterol transport in the clinic. Genetic alterations and factors involved in HDL functionality may be useful for quantifying HDL function and finding effective drugs to lower cardiovascular disease risk.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Statistical modeling of gut microbiota for personalized health status monitoring
Microbiome Open Access 18 August 2023
-
Changes in high-density lipoprotein cholesterol with risk of Cardiovascular Disease among initially high-density lipoprotein-high participants
Cardiovascular Diabetology Open Access 28 March 2023
-
Non-linear relationship between high-density lipoprotein cholesterol and incident diabetes mellitus: a secondary retrospective analysis based on a Japanese cohort study
BMC Endocrine Disorders Open Access 18 June 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rader, D.J., Alexander, E.T., Weibel, G.L., Billheimer, J. & Rothblat, G.H. J. Lipid Res. 50 Suppl, S189–S194 (2009).
Murphy, A.J., Westerterp, M., Yvan-Charvet, L. & Tall, A.R. Biochim. Biophys. Acta 1821, 513–521 (2012).
Zhang, Y. et al. Circulation 108, 661–663 (2003).
Nissen, S.E. et al. J. Am. Med. Assoc. 290, 2292–2300 (2003).
Wang, X. et al. J. Clin. Invest. 117, 2216–2224 (2007).
Yvan-Charvet, L. et al. J. Clin. Invest. 117, 3900–3908 (2007).
Naik, S.U. et al. Circulation 113, 90–97 (2006).
Rayner, K.J. et al. J. Clin. Invest. 121, 2921–2931 (2011).
Yvan-Charvet, L. et al. Science 328, 1689–1693 (2010).
Westerterp, M. et al. Cell Stem Cell 11, 195–206 (2012).
Dutta, P. et al. Nature 487, 325–329 (2012).
AIM-HIGH Investigators et al. N. Engl. J. Med. 365, 2255–2267 (2011).
Schwartz, G.G. et al. Am. Heart J. 158, 896–901 (2009).
Voight, B.F. et al. Lancet 380, 572–580 (2012).
Nordestgaard, B.G., Benn, M., Schnohr, P. & Tybjaerg-Hansen, A. J. Am. Med. Assoc. 298, 299–308 (2007).
Yvan-Charvet, L. et al. Arterioscler. Thromb. Vasc. Biol. 30, 1430–1438 (2010).
Khera, A.V. et al. N. Engl. J. Med. 364, 127–135 (2011).
Steinberg, D. J. Lipid Res. 47, 1339–1351 (2006).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
A.R.T. is a consultant for Merck, Pfizer, Roche, Amgen, CSL and Arisaph and receives research support from CSL.
Rights and permissions
About this article
Cite this article
Rader, D., Tall, A. Is it time to revise the HDL cholesterol hypothesis?. Nat Med 18, 1344–1346 (2012). https://doi.org/10.1038/nm.2937
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2937
This article is cited by
-
Changes in high-density lipoprotein cholesterol with risk of Cardiovascular Disease among initially high-density lipoprotein-high participants
Cardiovascular Diabetology (2023)
-
Statistical modeling of gut microbiota for personalized health status monitoring
Microbiome (2023)
-
Non-linear relationship between high-density lipoprotein cholesterol and incident diabetes mellitus: a secondary retrospective analysis based on a Japanese cohort study
BMC Endocrine Disorders (2022)
-
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
Current Atherosclerosis Reports (2022)
-
Ethanol-mediated upregulation of APOA1 gene expression in HepG2 cells is independent of de novo lipid biosynthesis
Lipids in Health and Disease (2020)